(350s) PLA-paclitaxel Nanoparticles in Lung Cancer Nano-Delivery Systems | AIChE

(350s) PLA-paclitaxel Nanoparticles in Lung Cancer Nano-Delivery Systems


Mai, N. Y. - Presenter, South Dakota School of Mines and Technology
Hoops, J., SD School of Mines
Kalaga, E. A., South Dakota School of Mines and Technology
Brenza, T., South Dakota Mines
Paclitaxel (PTX) or Taxol is widely used in chemotherapeutic treatment of breast, lung, Kaposi sarcoma and ovarian cancers. Besides effectiveness in therapy, paclitaxel causes various severe side effects by preventing healthy cell division. The hydrophobicity of paclitaxel is related to the performance of the drug. The formulation of paclitaxel in a nano-delivery systems is showing a promising future for cancer treatment. Polylactic acid (PLA) is a degradable polymer, non-toxic, degrades into generally regarded as safe monomers, and has shown compatibility with paclitaxel. Through localizing the release of PTX, this work aims to improve the efficacy of PTX against lung cancer. Emulsion techniques illustrate one approach to nanoparticle formation PTX at 0% (blank), 1% and 10% by mass was added to a polymer-solvent mixture and formulated into nanoparticles by a W/O/W emulsion with poly-vinyl alcohol (PVA) added as a surfactant Particle size and morphology of the particles were evaluated using scanning electron microscopy (SEM). The hydrodynamic diameter and surface charge of the particles were evaluated through the use of dynamic light scattering (DLS). The release kinetics of the nanoparticles were evaluated in buffer solution over time. Encapsulation efficiency (EE%) was calculated as the cumulative amount of drug released divided by the total drug amount added to the formulation. The efficacy of PTX loaded PLA-nanoparticles was tested against the A549 cell line, pulmonary adenocarcinoma epithelial cells. This study shows the potential of nano-carries as a drug delivery method for chemotherapeutics against lung cancer.